berberine has been researched along with Diseases, Metabolic in 17 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Berberine (BBR) is a botanic alkaloid extracted from Coptis chinensis (Huanglian), which has various properties, compassing anti-hyperglycemia, anti-obesity, anti-inflammation, and improves insulin resistance, etc." | 9.12 | Berberine as a Potential Multi-Target Agent for Metabolic Diseases: A Review of Investigations for Berberine. ( Cai, B; Chen, Q; Wang, S; Xu, Z, 2021) |
| "Berberine (BBR) is a multi-target drug (MTD) that has proven effective in the treatment of metabolism-related chronic diseases (CDs)." | 9.05 | Berberine in the treatment of metabolism-related chronic diseases: A drug cloud (dCloud) effect to target multifactorial disorders. ( Foiani, M; Jiang, JD; Kong, WJ; Vernieri, C, 2020) |
| " Berberine, an extraordinary medicinal herb, has been proven to have many clinical pharmacological effects, including lowering of blood glucose, increasing insulin sensitivity, and correcting lipid metabolism disorders." | 8.98 | Relationship Between Metabolic Disorders and Breast Cancer Incidence and Outcomes. Is There a Preventive and Therapeutic Role for Berberine? ( Bonanni, B; Cazzaniga, M, 2018) |
| "Berberine (BBR) is an eminent component of traditional Chinese and Ayurvedic medicine for more than 2000 years." | 6.61 | Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics. ( Annunziata, G; Barrea, L; Barreca, D; Feng, X; Hassan, STS; Jafari, S; Mahomoodally, MF; Malaník, M; Memariani, Z; Nabavi, SM; Shen, AZ; Šmejkal, K; Sureda, A; Sychrová, A; Tewari, D; Xu, S; Zengin, G; Ziberna, L, 2019) |
| " Various in vitro and in vivo studies have reported the anti-inflammatory role of berberine (BRB), an organic heteropentacyclic phytochemical and natural isoquinoline, in inhibiting NLRP3 inflammasome-dependent inflammation against many disorders." | 5.12 | Inhibitory Role of Berberine, an Isoquinoline Alkaloid, on NLRP3 Inflammasome Activation for the Treatment of Inflammatory Diseases. ( Abrahamse, H; George, BP; Sarbadhikary, P, 2021) |
| "Berberine (BBR) is a botanic alkaloid extracted from Coptis chinensis (Huanglian), which has various properties, compassing anti-hyperglycemia, anti-obesity, anti-inflammation, and improves insulin resistance, etc." | 5.12 | Berberine as a Potential Multi-Target Agent for Metabolic Diseases: A Review of Investigations for Berberine. ( Cai, B; Chen, Q; Wang, S; Xu, Z, 2021) |
| "Berberine (BBR) is a multi-target drug (MTD) that has proven effective in the treatment of metabolism-related chronic diseases (CDs)." | 5.05 | Berberine in the treatment of metabolism-related chronic diseases: A drug cloud (dCloud) effect to target multifactorial disorders. ( Foiani, M; Jiang, JD; Kong, WJ; Vernieri, C, 2020) |
| " Berberine, an extraordinary medicinal herb, has been proven to have many clinical pharmacological effects, including lowering of blood glucose, increasing insulin sensitivity, and correcting lipid metabolism disorders." | 4.98 | Relationship Between Metabolic Disorders and Breast Cancer Incidence and Outcomes. Is There a Preventive and Therapeutic Role for Berberine? ( Bonanni, B; Cazzaniga, M, 2018) |
| " Berberine, which is a modulator of TRPV1, has proven antiobesity and antidiabetic potentials." | 3.96 | Berberine attenuated olanzapine-induced metabolic alterations in mice: Targeting transient receptor potential vanilloid type 1 and 3 channels. ( Bansal, Y; Bishnoi, M; Kondepudi, KK; Kuhad, A; Medhi, B; Singh, DP; Singh, R; Sodhi, RK, 2020) |
| "Berberine is a plant metabolite belonging to the group of isoquinoline alkaloids with strong biological and pharmacological activity." | 2.66 | Biological Activity of Berberine-A Summary Update. ( Nowak, R; Och, A; Podgórski, R, 2020) |
| "Berberine (BBR) is an eminent component of traditional Chinese and Ayurvedic medicine for more than 2000 years." | 2.61 | Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics. ( Annunziata, G; Barrea, L; Barreca, D; Feng, X; Hassan, STS; Jafari, S; Mahomoodally, MF; Malaník, M; Memariani, Z; Nabavi, SM; Shen, AZ; Šmejkal, K; Sureda, A; Sychrová, A; Tewari, D; Xu, S; Zengin, G; Ziberna, L, 2019) |
| "Berberine is a quaternary ammonium salt from the protoberberine group of isoquinoline alkaloids found in such plants as gender Berberis." | 2.53 | Berberine: New Insights from Pharmacological Aspects to Clinical Evidences in the Management of Metabolic Disorders. ( Caliceti, C; Cicero, AF; Franco, P; Roda, A; Spinozzi, S, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (47.06) | 24.3611 |
| 2020's | 9 (52.94) | 2.80 |
| Authors | Studies |
|---|---|
| Sarbadhikary, P | 1 |
| George, BP | 1 |
| Abrahamse, H | 1 |
| Pu, Z | 1 |
| Sun, Y | 1 |
| Jiang, H | 1 |
| Hou, Q | 1 |
| Yan, H | 1 |
| Wen, H | 1 |
| Li, G | 1 |
| Cazzaniga, M | 2 |
| Zonzini, GB | 1 |
| Di Pierro, F | 1 |
| Moricoli, S | 1 |
| Bertuccioli, A | 1 |
| Ye, C | 1 |
| Zhang, Y | 1 |
| Lin, S | 1 |
| Chen, Y | 1 |
| Wang, Z | 1 |
| Feng, H | 1 |
| Fang, G | 1 |
| Quan, S | 1 |
| Kong, WJ | 1 |
| Vernieri, C | 1 |
| Foiani, M | 1 |
| Jiang, JD | 2 |
| Singh, R | 1 |
| Bansal, Y | 1 |
| Sodhi, RK | 1 |
| Singh, DP | 1 |
| Bishnoi, M | 1 |
| Kondepudi, KK | 1 |
| Medhi, B | 1 |
| Kuhad, A | 1 |
| Wang, S | 1 |
| Xu, Z | 1 |
| Cai, B | 1 |
| Chen, Q | 1 |
| Xu, X | 1 |
| Yi, H | 1 |
| Wu, J | 1 |
| Kuang, T | 1 |
| Zhang, J | 1 |
| Li, Q | 1 |
| Du, H | 1 |
| Xu, T | 1 |
| Jiang, G | 1 |
| Fan, G | 1 |
| Och, A | 1 |
| Podgórski, R | 1 |
| Nowak, R | 1 |
| Brown, BI | 1 |
| Bonanni, B | 1 |
| Feng, X | 1 |
| Sureda, A | 1 |
| Jafari, S | 1 |
| Memariani, Z | 1 |
| Tewari, D | 1 |
| Annunziata, G | 1 |
| Barrea, L | 1 |
| Hassan, STS | 1 |
| Šmejkal, K | 1 |
| Malaník, M | 1 |
| Sychrová, A | 1 |
| Barreca, D | 1 |
| Ziberna, L | 1 |
| Mahomoodally, MF | 1 |
| Zengin, G | 1 |
| Xu, S | 1 |
| Nabavi, SM | 1 |
| Shen, AZ | 1 |
| Guo, HH | 1 |
| Feng, CL | 1 |
| Zhang, WX | 1 |
| Luo, ZG | 1 |
| Zhang, HJ | 1 |
| Zhang, TT | 1 |
| Ma, C | 1 |
| Zhan, Y | 1 |
| Li, R | 1 |
| Wu, S | 1 |
| Abliz, Z | 1 |
| Li, C | 1 |
| Li, XL | 1 |
| Ma, XL | 1 |
| Wang, LL | 1 |
| Zheng, WS | 1 |
| Han, YX | 1 |
| Liu, Q | 1 |
| Yang, X | 1 |
| Chang, RC | 1 |
| Caliceti, C | 1 |
| Franco, P | 1 |
| Spinozzi, S | 1 |
| Roda, A | 1 |
| Cicero, AF | 1 |
| Shen, N | 1 |
| Li, CN | 1 |
| Huan, Y | 1 |
| Shen, ZF | 1 |
| Lin, H | 1 |
| Li, Z | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Assess the Effects of Berberine on Preventing Cardiovascular Disease and Diabetes Mellitus Among Individuals With High Cardiometabolic Risk[NCT05749874] | Phase 4 | 6,500 participants (Anticipated) | Interventional | 2023-04-01 | Not yet recruiting | ||
| A Phase I, Randomized, Crossover, Double-blind, Pharmacokinetic Study of Berberine Released From Cyclodextrin in Healthy Volunteers[NCT04918667] | Phase 1 | 16 participants (Anticipated) | Interventional | 2024-09-30 | Not yet recruiting | ||
| A Single-center, Randomized, Open-label, Controlled, Dose-escalating, Parallel-group Study to Assess the Anti-platelet Effect of Berberine in Patients Receiving Aspirin and Clopidogrel After Percutaneous Coronary Intervention[NCT03378934] | Phase 4 | 64 participants (Anticipated) | Interventional | 2018-09-26 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for berberine and Diseases, Metabolic
| Article | Year |
|---|---|
Inhibitory Role of Berberine, an Isoquinoline Alkaloid, on NLRP3 Inflammasome Activation for the Treatment of Inflammatory Diseases.
Topics: Animals; Anti-Inflammatory Agents; Berberine; Humans; Inflammasomes; Inflammation; Metabolic Disease | 2021 |
Berberine in the treatment of metabolism-related chronic diseases: A drug cloud (dCloud) effect to target multifactorial disorders.
Topics: Animals; Berberine; Chronic Disease; Drug Delivery Systems; Energy Metabolism; Humans; Metabolic Dis | 2020 |
Berberine as a Potential Multi-Target Agent for Metabolic Diseases: A Review of Investigations for Berberine.
Topics: Animals; Berberine; Drug Delivery Systems; Gastrointestinal Microbiome; Humans; Insulin Resistance; | 2021 |
Therapeutic effect of berberine on metabolic diseases: Both pharmacological data and clinical evidence.
Topics: Animals; Berberine; Biological Availability; Energy Metabolism; Humans; Metabolic Diseases; Signal T | 2021 |
Biological Activity of Berberine-A Summary Update.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Berberine; Cardiovascular Diseases; Drug R | 2020 |
Nutritional Management of Metabolic Endotoxemia: A Clinical Review.
Topics: Anti-Infective Agents; Berberine; Diet Therapy; Dysbiosis; Endotoxemia; Fermentation; Glutamine; Hum | 2017 |
Relationship Between Metabolic Disorders and Breast Cancer Incidence and Outcomes. Is There a Preventive and Therapeutic Role for Berberine?
Topics: Berberine; Blood Glucose; Breast Neoplasms; Female; Humans; Incidence; Insulin Resistance; Metabolic | 2018 |
Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics.
Topics: Animals; Berberine; Cardiovascular Diseases; Cardiovascular System; Humans; Metabolic Diseases | 2019 |
Berberine: New Insights from Pharmacological Aspects to Clinical Evidences in the Management of Metabolic Disorders.
Topics: Animals; Berberine; Humans; Metabolic Diseases | 2016 |
[Advances of the mechanism study on berberine in the control of blood glucose and lipid as well as metabolism disorders].
Topics: AMP-Activated Protein Kinase Kinases; Animals; Berberine; Blood Glucose; Coptis; Diabetes Mellitus; | 2010 |
1 trial available for berberine and Diseases, Metabolic
| Article | Year |
|---|---|
Effects of Berberine on Gut Microbiota in Patients with Mild Metabolic Disorders Induced by Olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Berberine; Gastrointestinal Microbiome; Humans; Metabolic Dis | 2021 |
6 other studies available for berberine and Diseases, Metabolic
| Article | Year |
|---|---|
Gut Microbiota, Metabolic Disorders and Breast Cancer: Could Berberine Turn Out to Be a Transversal Nutraceutical Tool? A Narrative Analysis.
Topics: Berberine; Breast Neoplasms; Butyrates; Dysbiosis; Estrogens; Fatty Acids, Volatile; Female; Gastroi | 2022 |
Berberine Ameliorates Metabolic-Associated Fatty Liver Disease Mediated Metabolism Disorder and Redox Homeostasis by Upregulating Clock Genes: Clock and Bmal1 Expressions.
Topics: Animals; ARNTL Transcription Factors; Berberine; Glucosamine; Hep G2 Cells; Homeostasis; Humans; Hyd | 2023 |
Berberine attenuated olanzapine-induced metabolic alterations in mice: Targeting transient receptor potential vanilloid type 1 and 3 channels.
Topics: Animals; Antipsychotic Agents; Berberine; Body Temperature; Body Weight; Cytokines; Drinking; Female | 2020 |
Liver-target nanotechnology facilitates berberine to ameliorate cardio-metabolic diseases.
Topics: Animals; Berberine; Caco-2 Cells; Cardiovascular Diseases; Dyslipidemias; Hep G2 Cells; Humans; Hypo | 2019 |
Editorial: Bioactive Small Molecules in Regulating Inflammation and Metabolic Disorder.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Berberine; Humans; Inflammation; Metabol | 2016 |
Adiponectin self-regulates its expression and multimerization in adipose tissue: an autocrine/paracrine mechanism?
Topics: Adiponectin; Adipose Tissue; Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Autocrine Co | 2012 |